MedPath

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Phase 2
Terminated
Conditions
Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis
Interventions
Registration Number
NCT03059446
Lead Sponsor
Tobira Therapeutics, Inc.
Brief Summary

This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
167
Inclusion Criteria
  • Successful completion of both Treatment Period 1 and Treatment Period 2, of the CENTAUR Study (652-2-203), including a Year 2 liver biopsy.
  • Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated liver-related clinical outcome in Part 1 or Part 2 of the study of:
  • Histopathological progression to cirrhosis
  • Model for end-stage liver disease (MELD) score ≥ 15
  • Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a diuretic)
  • Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed, hepatic encephalopathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid bacterial culture).
Exclusion Criteria
  • Prior or planned liver transplantation
  • Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's disease, hemochromatosis, or iron overload, or Alpha-1 antitrypsin (A1AT) deficiency.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cenicriviroc (CVC) 150 mgCenicrivirocCenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).
Primary Outcome Measures
NameTimeMethod
Number of Participants With Treatment-emergent Adverse Events (AE)Day 1 until the study was terminated (up to approximately 4 years)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. A treatment-emergent AE is an AE that occurs after a participant receives study drug.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (71)

Universitaetsklinikum Heidelberg - Innere Medizin IV

🇩🇪

Heidelberg, Germany

Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP)

🇩🇪

Koeln, Germany

Queen Alexandra Hospital

🇬🇧

Portsmouth, United Kingdom

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano

🇮🇹

Milano, Italy

Hospital de la Santa Creu i Sant Pau Barcelona

🇪🇸

Barcelona, Spain

Hospital General Universitario Gregorio Maranon

🇪🇸

Madrid, Spain

Nottingham NHS Treatment Centre

🇬🇧

Nottingham, United Kingdom

Antwerp University Hospital (UZA)

🇧🇪

Edegem, Belgium

Delta Research Partners, Llc

🇺🇸

Bastrop, Louisiana, United States

Fundacion de Investigacion de Diego

🇵🇷

San Juan, Puerto Rico

Adobe Clinical Research, LLC

🇺🇸

Tucson, Arizona, United States

Tandem Clinical Research LLC

🇺🇸

Marrero, Louisiana, United States

Digestive Health Specialists

🇺🇸

Tupelo, Mississippi, United States

Austin Health

🇦🇺

Heidelberg, Victoria, Australia

Johns Hopkins University School of Medicine

🇺🇸

Baltimore, Maryland, United States

Uniklinik RWTH Aachen

🇩🇪

Aachen, Germany

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Mayo Clinic Hospital

🇺🇸

Phoenix, Arizona, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Duke University Medical Center (DUMC)

🇺🇸

Durham, North Carolina, United States

The University of Texas - Health Science Center & Medical School at Houston

🇺🇸

Houston, Texas, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Franco Felizarta, MDv

🇺🇸

Bakersfield, California, United States

Kansas Medical Clinic PA

🇺🇸

Topeka, Kansas, United States

University of Iowa Hospital and Clinics

🇺🇸

Iowa City, Iowa, United States

University of California, San Diego (UCSD) - Medical Center

🇺🇸

San Diego, California, United States

University of California, San Diego (UCSD)

🇺🇸

La Jolla, California, United States

Quest Clinical Research

🇺🇸

San Francisco, California, United States

Inland Empire Liver Foundation

🇺🇸

Rialto, California, United States

Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Upland Clinical Research

🇺🇸

Upland, California, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Minnesota Gastroenterology, P.A.

🇺🇸

Saint Paul, Minnesota, United States

University of Buffalo - Erie County Medical Center

🇺🇸

Buffalo, New York, United States

PMG Research of Winston-Salem, LLC

🇺🇸

Winston-Salem, North Carolina, United States

Options Health Research, LLC

🇺🇸

Tulsa, Oklahoma, United States

ClinSearch LLC

🇺🇸

Chattanooga, Tennessee, United States

Digestive Health Research

🇺🇸

Lebanon, Tennessee, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Virginia Mason Medical Center

🇺🇸

Seattle, Washington, United States

Hopital Saint Antoine

🇫🇷

Paris, France

The Texas Liver Institute

🇺🇸

San Antonio, Texas, United States

Royal Brisbane Hospital and Women's Hospital

🇦🇺

Herston, Queensland, Australia

Central Adelaide Local Health Network Inc - Royal Adelaide Hospital

🇦🇺

Adelaide, South Australia, Australia

Purpan CHU Toulouse

🇫🇷

Toulouse, cedex 9, France

Universitaetsklinikum Hamburg-Eppendorf - I. Medizinische Klinik und Poliklinik

🇩🇪

Hamburg, Germany

Prince of Wales Hospital

🇭🇰

Shatin, Hong Kong

Policlinico S. Orsola-Malpighi

🇮🇹

Bologna, Italy

AOU Policlinico Paolo Giaccone di Palermo

🇮🇹

Palermo, Italy

University Hospital Giessen and Marburg GmbH

🇩🇪

Marburg, Germany

Hospital Universitario Vall d'Hebron

🇪🇸

Barcelona, Spain

ID Clinic

🇵🇱

Myslowice, Poland

Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p.

🇵🇱

Wroclaw, Poland

Charite - University Hospital Berlin - Campus Virchow - Hospital

🇩🇪

Berlin, Germany

Digestive Health Specialists of the Southeast - Dothan

🇺🇸

Dothan, Alabama, United States

Consultants for Clinical Research - Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

Wake Research Associates, LLC - Raleigh

🇺🇸

Raleigh, North Carolina, United States

Eugastro GmbH

🇩🇪

Leipzig, Germany

Advanced Medical Research

🇺🇸

Port Orange, Florida, United States

Island View Gastroenterology Associates

🇺🇸

Ventura, California, United States

University of Miami - Schiff Center for Liver Diseases

🇺🇸

Miami, Florida, United States

Tulane University Medical Center

🇺🇸

New Orleans, Louisiana, United States

Mercy Medical Center - Baltimore, Maryland

🇺🇸

Baltimore, Maryland, United States

Gastro One

🇺🇸

Germantown, Tennessee, United States

Flinders Medical Centre

🇦🇺

Bedford Park, South Australia, Australia

Virginia Commonwealth University Medical College of Virginia

🇺🇸

Richmond, Virginia, United States

CHU Angers

🇫🇷

Angers Cedex 09, France

Monash Medical Centre

🇦🇺

Clayton, Victoria, Australia

UCL Saint Luc Bruxelles

🇧🇪

Brussel, Belgium

University Hospital Erasmus (Brussels)

🇧🇪

Bruxelles, Belgium

© Copyright 2025. All Rights Reserved by MedPath